Professor Gordon McInnes
- Honorary Senior Research Fellow (Undergraduate Medical School)
email:
Gordon.McInnes@glasgow.ac.uk
Institute of C&MS, Western Infirmary, 44 Church Street, G11 6nt
Publications
2021
Gumley, A. , Glasgow, A., McInnes, G. and Jackson, C. (2021) Mental health professionals’ positions in relation to advance statements: a Foucauldian discourse analysis. Qualitative Health Research, 31(13), pp. 2378-2389. (doi: 10.1177/10497323211036893) (PMID:34382884)
2018
Williams, B. et al. (2018) Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes and Endocrinology, 6(6), pp. 464-475. (doi: 10.1016/S2213-8587(18)30071-8) (PMID:29655877) (PMCID:PMC5966620)
2017
MacDonald, T. M. et al. (2017) Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. Journal of the American Heart Association, 6(11), e006986. (doi: 10.1161/JAHA.117.006986) (PMID:29151036) (PMCID:PMC5721778)
2016
Alharf, A.A., Cleland, S., Webster, J., McInnes, G.T. and Padmanabhan, S. (2016) Microalbuminuria in subjects with hypertension attending specialist blood pressure clinics. Journal of Human Hypertension, 30(9), pp. 527-533. (doi: 10.1038/jhh.2015.116) (PMID:26674756)
Lip, S. , Jeemon, P., Mccallum, L., Dominiczak, A. F. , McInnes, G. T. and Padmanabhan, S. (2016) Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. European Heart Journal, 374(12), (doi: 10.1093/eurheartj/ehv557) (PMID:26508167)
Brown, M. J. et al. (2016) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes and Endocrinology, 4(2), pp. 136-147. (doi: 10.1016/s2213-8587(15)00377-0) (PMID:26489809) (PMCID:PMC4728199)
2015
Williams, B. et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, 386(10008), pp. 2059-2068. (doi: 10.1016/S0140-6736(15)00257-3) (PMID:26414968) (PMCID:PMC4655321)
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q. and Kothny, W. (2015) Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes, Obesity and Metabolism, 17(11), pp. 1085-1092. (doi: 10.1111/dom.12548) (PMID:26250051)
Fulton, R. L., Walters, M. R. , Morton, R., Touyz, R. M. , Dominiczak, A. F. , Morrison, D. S., Padmanabhan, S. , Meredith, P. A., McInnes, G. T. and Dawson, J. (2015) Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension, 65(5), 1008-U596. (doi: 10.1161/HYPERTENSIONAHA.114.04945) (PMID:25801870)
MacDonald, T. M. et al. (2015) Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: figure 1. BMJ Open, 5(8), e007645. (doi: 10.1136/bmjopen-2015-007645) (PMID:26253566) (PMCID:PMC4539389)
Williams, B. et al. (2015) Prevention And treatment of hypertension with algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open, 5(8), e008951. (doi: 10.1136/bmjopen-2015-008951) (PMID:26253568) (PMCID:PMC4538257)
2014
McCallum, L. et al. (2014) Response to effect of serum chloride on mortality in hypertensive patients. Hypertension, 63(3), e15-e15. (doi: 10.1161/HYPERTENSIONAHA.113.02926)
2013
McCallum, L. et al. (2013) Serum chloride is an independent predictor of mortality in hypertensive patients. Hypertension, 62(5), pp. 836-843. (doi: 10.1161/HYPERTENSIONAHA.113.01793)
Aubini è re-Robb, L. et al. (2013) Blood pressure response to patterns of weather fluctuations and effect on mortality. Hypertension, 62(1), pp. 190-196. (doi: 10.1161/HYPERTENSIONAHA.111.00686)
Dawson, J. et al. (2013) Acetaminophen use and change in blood pressure in a hypertensive population. Journal of Hypertension, 31(7), pp. 1485-1490. (doi: 10.1097/HJH.0b013e328360f6f8)
Dawson, J. et al. (2013) Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension, 62(1), pp. 105-111. (doi: 10.1161/HYPERTENSIONAHA.113.00859)
Hastie, C. et al. (2013) Long-term and ultra-long term blood pressure variability during follow–up and mortality in 14522 patients with hypertension. Hypertension, 62(4), pp. 698-705. (doi: 10.1161/HYPERTENSIONAHA.113.01343) (PMID:23959561)
Higgins, P., Macfarlane, P. W., Dawson, J. , McInnes, G. T., Langhorne, P. and Lees, K. R. (2013) Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke, 44(9), pp. 2525-2531. (doi: 10.1161/STROKEAHA.113.001927)
2012
Weber, M.A. et al. (2012) Cardiovascular outcomes in hypertensive patients. Journal of Hypertension, 30(11), pp. 2213-2222. (doi: 10.1097/HJH.0b013e3283582ed6)
Paul, L. et al. (2012) Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults. Hypertension, 60(3), pp. 631-638. (doi: 10.1161/HYPERTENSIONAHA.112.191510)
McInnes, G. (2012) Pre-hypertension: how low to go and do drugs have a role? British Journal of Clinical Pharmacology, 73(2), pp. 187-193. (doi: 10.1111/j.1365-2125.2011.04092.x)
2011
Cohn, J.N., McInnes, G.T. and Shepherd, A.M. (2011) Direct-acting vasodilators. Journal of Clinical Hypertension, 13(9), pp. 690-692. (doi: 10.1111/j.1751-7176.2011.00507.x)
Parthasarathy, H.K., Ménard, J., White, W.B., Young, W.F., Williams, G.H., Williams, B., Ruilope, L.M., McInnes, G.T., Connell, J.M. and MacDonald, T.M. (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension, 29(5), pp. 980-990. (doi: 10.1097/HJH.0b013e3283455ca5)
Brown, M.J., McInnes, G.T., Papst, C.C., Zhang, J. and MacDonald, T.M. (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet, 377(9762), pp. 312-320. (doi: 10.1016/S0140-6736(10)62003-X)
Cameron, A., Dawson, J. , Quinn, T.J. , Walters, M.R. , McInnes, G.T., Morrison, D., Sloan, W. and Lees, K.R. (2011) Long-term outcome following attendance at a transient ischemic attack clinic. International Journal of Stroke, 6(4), pp. 306-311. (doi: 10.1111/j.1747-4949.2011.00591.x)
McInnes, G.T. (2011) The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors. Journal of Human Hypertension, 25(6), p. 343. (doi: 10.1038/jhh.2011.12)
2010
Paul, L., Hastie, C. E. , Li, W. S., Harrow, C., Muir, S., Connell, J. M.C., Dominiczak, A. F. , McInnes, G. T. and Padmanabhan, S. (2010) Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension, 55(2), pp. 567-574. (doi: 10.1161/HYPERTENSIONAHA.109.144808)
Parthasarathy, H. K., Alhashmi, K., McMahon, A. D. , Struthers, A. D., McInnes, G. T., Ford, I. , Connell, J. M. and MacDonald, T. M. (2010) Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension, 28(1), pp. 170-177. (doi: 10.1097/HJH.0b013e328332b79b)
Meredith, P.A. and McInnes, G.T. (2010) Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncology, 11(9), p. 819. (doi: 10.1016/S1470-2045(10)70163-7)
Meredith, P.A., Murray, L. and McInnes, G.T. (2010) Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. Journal of Human Hypertension, 24(8), pp. 525-531. (doi: 10.1038/jhh.2009.99)
2009
Dolan, E., Stanton, A., Thom, S., Caulfield, M., Atkins, N., McInnes, G., Collier, D., Dicker, P. and O'Brien, E. (2009) Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - an Anglo-Scandinavian cardiac outcomes trial substudy. Journal of Hypertension, 27(4), pp. 876-885.
McInnes, G. T. (2009) Drug treatment of prehypertension: Not now, not ever? Blood Pressure, 18(6), pp. 304-307. (doi: 10.3109/08037050903416436)
McInnes, G.T. (2009) Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? Stroke, 40(5), pp. 1938-1940. (doi: 10.1161/STROKEAHA.108.541276)
McMahon, A. D. , Conway, D. I. , MacDonald, T. M. and McInnes, G. T. (2009) The unintended consequences of clinical trials regulations. PLoS Medicine, 6(11), e1000131. (doi: 10.1371/journal.pmed.1000131)
Stewart, L., McInnes, G.T., Murray, L., Sloan, B., Walters, M., Morton, R., Padmanabhan, S., Reid, J.L. and Morrison, D.S. (2009) Risks of socioeconomic deprivation on mortality in hypertensive patients. Journal of Hypertension, 27(4), pp. 730-735. (doi: 10.1097/HJH.0b013e328324ed58)
2008
McManus, F., McInnes, G. T. and McConnell, J. M. C. (2008) Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nature Reviews Endocrinology, 4(1), pp. 44-52. (doi: 10.1038/ncpendmet0676)
Kjeldsen, S. et al. (2008) Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure, 17(3), pp. 170-177. (doi: 10.1080/08037050802169644)
Schmieder, R., Kjeldsen, S., Julius, S., McInnes, G., Zanchetti, A. and Hua, T. (2008) Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of Hypertension, 26(3), pp. 403-411.
2007
Hua, T., Jamerson, K., Julius, S., McInnes, G., Ruilope, L., Segura, J., Stolt, P., Weber, M. and Zanchetti, A. (2007) Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. Journal of Hypertension, 25, pp. 1473-1479.
McInnes, G.T. (2007) Diabetes and hypertension. In: Fisher, M. and McMurray, J.J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. Wiley: Chichester, pp. 135-174. ISBN 9780470862049
McInnes, G. (2007) Antihypertensive drugs in combination: additive or greater than additive? Journal of Human Hypertension, 21(12), pp. 914-916.
McInnes, G. (2007) Renin inhibition: the holy grail of renin-angiotensin system blockade? Journal of Human Hypertension, 21(10), pp. 766-769.
McInnes, G. (2007) What is the true place of blood pressure in cardiovascular risk management? Journal of Hypertension, 25, pp. 925-928.
Parthasarathy, H.K., Alhashmi, K., McMahon, A., Struthers, A.D., Connell, J.M.C., McInnes, G.T., Ford, I. and MacDonald, T.M. (2007) Does the aldosterone : renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. BMC Cardiovascular Disorders, 7(14), (doi: 10.1186/1471-2261-7-14)
Rennie, I.G. and McInnes, G.T. (2007) Medication. In: Cox, R.A.F., Brown, I. and Palmer, K.T. (eds.) Fitness for Work: the Medical Aspects. Oxford University Press: Oxford, pp. 547-562. ISBN 9780199215652
2006
Amerena, J. et al. (2006) The valsartan antihypertensive long-term use evaluation (VALUE) trial - Outcomes in patients receiving monotherapy. Hypertension, 48, pp. 385-391. (doi: 10.1161/01.HYP.0000236119.96301.f2)
Coca, A. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension, 24(7), pp. 1405-1412.
MacDonald, T., McInnes, G., Mitchell, M., Patterson, D. and Webster, J. (2006) Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. British Journal of Clinical Pharmacology, 62(3), pp. 280-287.
McInnes, G., Burke, T. and Carides, G. (2006) Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Journal of Human Hypertension, 20, pp. 51-58. (doi: 10.1038/sj.jhh.1001939)
Sever, P. et al. (2006) Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal, 27, pp. 2982-2988. (doi: 10.1093/eurheartj/ehl403)
Zanchetti, A., Julius, S., Kjeldsen, S., McInnes, G., Hua, T., Weber, M., Laragh, J. and Plat, F. (2006) Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from value. Journal of Hypertension, 24, S4-S4.
2005
Aslanyan, S., Weir, C., McInnes, G., Reid, J., Walters, M. and Lees, K. (2005) Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. European Journal of Neurology, 12, pp. 493-498.
Beevers, D. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A. Lancet, 366(9489), pp. 895-906.
Beevers, D. et al. (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 366, pp. 907-913. (doi: 10.1016/S0140-6736(05)67186-3)
Beevers, G. et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care, 28, pp. 1151-1157.
Dahlof, B. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B. Lancet, 366, pp. 895-906. (doi: 10.1016/S0140-6736(05)67185-1)
Julius, S. et al. (2005) The VALUE trial. In: Oparil, S. and Weber, M.A. (eds.) Hypertension: A Companion to Brenner and Rector's The Kidney. Elsevier Mosby: Philadelphia, USA, pp. 366-375. ISBN 9780721602585
McInnes, G.T. (2005) Critical assessment of hypertension guidelines. In: Weber, M.A. (ed.) Hypertension: A Companion Guide to Brenner and Rector's the Kidney. Elsevier: Philadelphia, pp. 391-399. ISBN 9780721602585
McInnes, G. (2005) Antioxidants and hypertension: another false dawn? Journal of Hypertension, 23(11), pp. 1963-1966.
McInnes, G. (2005) Lowering blood pressure for cardiovascular risk reduction. Journal of Hypertension, 23, S3-S8.
McInnes, G., Ruilope, L., Volpe, M., Waeber, B. and Weber, M. (2005) Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? Journal of Human Hypertension, 19, pp. 331-339. (doi: 10.1038/sj.jhh.1001831)
Stergiou, G., Efstathiou, S., Inglis, G., Connell, J., McInnes, G. and Mountokalakis, T. (2005) Association of renin-angiotensin system gene polymorphisms with antihypertensive responses to angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Journal of Human Hypertension, 19, pp. 971-974. (doi: 10.1038/sj.jhh.1001918)
2004
Weber, M.A. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 363(9426), pp. 2049-2051. (doi: 10.1016/S0140-6736(04)16456-8)
McInnes, G.T. (2004) How important is optimal blood pressure control? Clinical Therapeutics, 26(Suppl.), A3-A11. (doi: 10.1016/S0149-2918(04)90140-3)
Beevers, G. et al. (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre r. Drugs, 64, pp. 43-60.
Bohm, M., McInnes, G., Neutel, J. and Unger, T. (2004) The role of olmesartan medoxomil in the management of hypertension. Drugs, 64, pp. 2731-2739.
Brown, M., Davis, M., McInnes, G., Potter, J., Poulter, N., Sever, P., Thom, S. and Williams, B. (2004) Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHSIV. Journal of Human Hypertension, 18, pp. 139-185. (doi: 10.1038/sj.jhh.1001683)
Brown, M., Davis, M., McInnes, G., Potter, M., Poulter, N., Sever, P., Thom, S. and Williams, B. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. British Medical Journal, 328, pp. 634-640.
Kjeldsen, S. and McInnes, G. (2004) Never mind the quality, feel the width - ALLHAT revisited. Blood Pressure, 13, pp. 330-334. (doi: 10.1080/08037050410004576)
McInnes, G.T., Curzio, J.L. and Kennedy, S. (2004) Hypertension and antihypertensive therapy. In: Lindsay, G.M. and Gaw, A. (eds.) Coronary Heart Disease Prevention: A Handbook for the Health-Care Team. Churchill Livingstone: Edinburgh, UK. ISBN 9780443071171
McInnes, G. (2004) Hypertension control - An old song resung. Blood Pressure, 13(2), pp. 69-71.
McInnes, G. (2004) What lies behind the intense criticism of ALLHAT? Reply. Journal of Hypertension, 22(1), pp. 226-227.
Sever, P. et al. (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre randomi. Drugs, 64, pp. 43-60.
2003
Aslanyan, S., Lees, K., McInnes, G., Reid, J. and Weir, C. (2003) Effect of area-based deprivation on the severity, subtype, and outcome of ischemic stroke. Stroke, 34, pp. 2623-2628. (doi: 10.1161/01.STR.0000097610.12803.D7)
Beevers, G. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre ran. Lancet, 361(9364), pp. 1149-1158.
Elliot, H.L. and McInnes, G.T. (2003) Calcium channel blockers in profile. In: Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services Limited: Oxford, pp. 323-336. ISBN 9780953733941
Elliot, H.J., Connell, J.M.C. and McInnes, G.T. (2003) Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK. ISBN 9780953733941
Julius, S. et al. (2003) VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. American Journal of Hypertension, 16, pp. 544-548. (doi: 10.1016/S0895-7061(03)00904-X)
MacDonald, T., McInnes, G. and Wong, S. (2003) Why not prescribe the best drugs for hypertension now? Journal of Human Hypertension, 17(7), pp. 505-511.
Mancia, G. et al. (2003) 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension, 21, pp. 1011-1053. (doi: 10.1097/01.hjh.0000059051.65882.32)
McInnes, G.T. (2003) Ongoing trials. In: Elliott, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 89-126. ISBN 9780953733941
McInnes, G.T. (2003) Recent trial results. In: Elliot, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 2-34. ISBN 9780953733941
McInnes, G. (2003) ALLHAT: a saga of missed opportunities. Journal of Human Hypertension, 17(6), pp. 373-377.
McInnes, G. (2003) The expanding role of angiotension receptor blockers in the management of the elderly hypertensive. Current Medical Research and Opinion, 19, pp. 452-455. (doi: 10.1185/030079903125001992)
McInnes, G. (2003) Introduction: the role of angiotensin receptor blockers in preventing stroke and cognitive decline. Current Medical Research and Opinion, 19(5), p. 437.
McInnes, G. (2003) Size isn't everything - ALLHAT in perspective. Journal of Hypertension, 21(3), pp. 459-461.
Patterson, D., Webster, J., McInnes, G., Brady, A. and MacDonald, T. (2003) The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension. British Journal of Clinical Pharmacology, 56, pp. 513-519. (doi: 10.1046/j.1365-2125.2003.01932.x)
Sever, P. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomise. Lancet, 361, pp. 1149-1158.
2002
Elliott, H.I. and McInnes, G.T. (2002) Special management needs of the elderly hypertensive patient. Journal of the Renin-Angiotensin-Aldosterone System, 3, S25-S31.
McInnes, G. (2002) Evidence-based management of hypertension. In: Horizons in Medicine Vol. 13. Royal College of Physicians: London. ISBN 1-86016-154-5
McInnes, G. (2002) Clinical trials and tribulations. Clinical and Experimental Pharmacology and Physiology, 29, pp. 951-955.
McInnes, G. (2002) Olmesartan medoxomil. Drugs, 62(9), p. 1356.
McInnes, G. (2002) Systolic hypertension as a cardiovascular risk factor. Blood Pressure, 11, pp. 134-143.
2001
Atkins, N., Caulfield, M., McInnes, G., Nichol, F., O'Brien, E., Stanton, A. and Thom, S. (2001) Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients. Journal of Human Hypertension, 15, S47-S51.
Beevers, G. et al. (2001) Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. Journal of Human Hypertension, 15, S11-S12.
Beevers, G. et al. (2001) Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. Journal of Hypertension, 19, pp. 1139-1147.
Dahlof, B. et al. (2001) Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension, 19, pp. 1149-1159.
Kjeldsen, S. et al. (2001) Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Pressure, 10, pp. 83-91.
McInnes, G.T. (2001) Current guidelines. In: Elliott, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 43-88. ISBN 9780953733941
McInnes, G.T. (2001) Diuretics. In: Aronson, J.K. (ed.) Side Effects of Drugs Annual 24: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions. Elsevier: Amsterdam, The Netherlands, pp. 246-252. ISBN 9780444505125
McInnes, G. (2001) Angiotensin II antagonists in systolic blood pressure control. Hospital Medicine, 62, pp. 773-777.
McInnes, G. (2001) Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonists? Journal of Hypertension, 19(Suppl.), S61-S67.
McInnes, G. (2001) Debate: Does it matter how you lower blood pressure? Current Controlled Trials in Cardiovascular Medicine, 2(2), pp. 63-66.
McInnes, G. (2001) Lessons from the recent trials on hypertension treatment. Nephrology Dialysis Transplantation, 16, pp. 43-45.
1992
McMurray, J. and McInnes, G. T. (1992) The J-curve hypothesis. Lancet, 339(8792), pp. 561-562. (doi: 10.1016/0140-6736(92)90390-o) (PMID:1346917)
Articles
Gumley, A. , Glasgow, A., McInnes, G. and Jackson, C. (2021) Mental health professionals’ positions in relation to advance statements: a Foucauldian discourse analysis. Qualitative Health Research, 31(13), pp. 2378-2389. (doi: 10.1177/10497323211036893) (PMID:34382884)
Williams, B. et al. (2018) Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes and Endocrinology, 6(6), pp. 464-475. (doi: 10.1016/S2213-8587(18)30071-8) (PMID:29655877) (PMCID:PMC5966620)
MacDonald, T. M. et al. (2017) Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. Journal of the American Heart Association, 6(11), e006986. (doi: 10.1161/JAHA.117.006986) (PMID:29151036) (PMCID:PMC5721778)
Alharf, A.A., Cleland, S., Webster, J., McInnes, G.T. and Padmanabhan, S. (2016) Microalbuminuria in subjects with hypertension attending specialist blood pressure clinics. Journal of Human Hypertension, 30(9), pp. 527-533. (doi: 10.1038/jhh.2015.116) (PMID:26674756)
Lip, S. , Jeemon, P., Mccallum, L., Dominiczak, A. F. , McInnes, G. T. and Padmanabhan, S. (2016) Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes. European Heart Journal, 374(12), (doi: 10.1093/eurheartj/ehv557) (PMID:26508167)
Brown, M. J. et al. (2016) Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial. Lancet Diabetes and Endocrinology, 4(2), pp. 136-147. (doi: 10.1016/s2213-8587(15)00377-0) (PMID:26489809) (PMCID:PMC4728199)
Williams, B. et al. (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet, 386(10008), pp. 2059-2068. (doi: 10.1016/S0140-6736(15)00257-3) (PMID:26414968) (PMCID:PMC4655321)
McInnes, G., Evans, M., Del Prato, S., Stumvoll, M., Schweizer, A., Lukashevich, V., Shao, Q. and Kothny, W. (2015) Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients. Diabetes, Obesity and Metabolism, 17(11), pp. 1085-1092. (doi: 10.1111/dom.12548) (PMID:26250051)
Fulton, R. L., Walters, M. R. , Morton, R., Touyz, R. M. , Dominiczak, A. F. , Morrison, D. S., Padmanabhan, S. , Meredith, P. A., McInnes, G. T. and Dawson, J. (2015) Acetaminophen use and risk of myocardial infarction and stroke in a hypertensive cohort. Hypertension, 65(5), 1008-U596. (doi: 10.1161/HYPERTENSIONAHA.114.04945) (PMID:25801870)
MacDonald, T. M. et al. (2015) Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: figure 1. BMJ Open, 5(8), e007645. (doi: 10.1136/bmjopen-2015-007645) (PMID:26253566) (PMCID:PMC4539389)
Williams, B. et al. (2015) Prevention And treatment of hypertension with algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open, 5(8), e008951. (doi: 10.1136/bmjopen-2015-008951) (PMID:26253568) (PMCID:PMC4538257)
McCallum, L. et al. (2014) Response to effect of serum chloride on mortality in hypertensive patients. Hypertension, 63(3), e15-e15. (doi: 10.1161/HYPERTENSIONAHA.113.02926)
McCallum, L. et al. (2013) Serum chloride is an independent predictor of mortality in hypertensive patients. Hypertension, 62(5), pp. 836-843. (doi: 10.1161/HYPERTENSIONAHA.113.01793)
Aubini è re-Robb, L. et al. (2013) Blood pressure response to patterns of weather fluctuations and effect on mortality. Hypertension, 62(1), pp. 190-196. (doi: 10.1161/HYPERTENSIONAHA.111.00686)
Dawson, J. et al. (2013) Acetaminophen use and change in blood pressure in a hypertensive population. Journal of Hypertension, 31(7), pp. 1485-1490. (doi: 10.1097/HJH.0b013e328360f6f8)
Dawson, J. et al. (2013) Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. Hypertension, 62(1), pp. 105-111. (doi: 10.1161/HYPERTENSIONAHA.113.00859)
Hastie, C. et al. (2013) Long-term and ultra-long term blood pressure variability during follow–up and mortality in 14522 patients with hypertension. Hypertension, 62(4), pp. 698-705. (doi: 10.1161/HYPERTENSIONAHA.113.01343) (PMID:23959561)
Higgins, P., Macfarlane, P. W., Dawson, J. , McInnes, G. T., Langhorne, P. and Lees, K. R. (2013) Noninvasive cardiac event monitoring to detect atrial fibrillation after ischemic stroke: a randomized, controlled trial. Stroke, 44(9), pp. 2525-2531. (doi: 10.1161/STROKEAHA.113.001927)
Weber, M.A. et al. (2012) Cardiovascular outcomes in hypertensive patients. Journal of Hypertension, 30(11), pp. 2213-2222. (doi: 10.1097/HJH.0b013e3283582ed6)
Paul, L. et al. (2012) Hematocrit predicts long-term mortality in a nonlinear and sex-specific manner in hypertensive adults. Hypertension, 60(3), pp. 631-638. (doi: 10.1161/HYPERTENSIONAHA.112.191510)
McInnes, G. (2012) Pre-hypertension: how low to go and do drugs have a role? British Journal of Clinical Pharmacology, 73(2), pp. 187-193. (doi: 10.1111/j.1365-2125.2011.04092.x)
Cohn, J.N., McInnes, G.T. and Shepherd, A.M. (2011) Direct-acting vasodilators. Journal of Clinical Hypertension, 13(9), pp. 690-692. (doi: 10.1111/j.1751-7176.2011.00507.x)
Parthasarathy, H.K., Ménard, J., White, W.B., Young, W.F., Williams, G.H., Williams, B., Ruilope, L.M., McInnes, G.T., Connell, J.M. and MacDonald, T.M. (2011) A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism. Journal of Hypertension, 29(5), pp. 980-990. (doi: 10.1097/HJH.0b013e3283455ca5)
Brown, M.J., McInnes, G.T., Papst, C.C., Zhang, J. and MacDonald, T.M. (2011) Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet, 377(9762), pp. 312-320. (doi: 10.1016/S0140-6736(10)62003-X)
Cameron, A., Dawson, J. , Quinn, T.J. , Walters, M.R. , McInnes, G.T., Morrison, D., Sloan, W. and Lees, K.R. (2011) Long-term outcome following attendance at a transient ischemic attack clinic. International Journal of Stroke, 6(4), pp. 306-311. (doi: 10.1111/j.1747-4949.2011.00591.x)
McInnes, G.T. (2011) The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors. Journal of Human Hypertension, 25(6), p. 343. (doi: 10.1038/jhh.2011.12)
Paul, L., Hastie, C. E. , Li, W. S., Harrow, C., Muir, S., Connell, J. M.C., Dominiczak, A. F. , McInnes, G. T. and Padmanabhan, S. (2010) Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension, 55(2), pp. 567-574. (doi: 10.1161/HYPERTENSIONAHA.109.144808)
Parthasarathy, H. K., Alhashmi, K., McMahon, A. D. , Struthers, A. D., McInnes, G. T., Ford, I. , Connell, J. M. and MacDonald, T. M. (2010) Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. Journal of Hypertension, 28(1), pp. 170-177. (doi: 10.1097/HJH.0b013e328332b79b)
Meredith, P.A. and McInnes, G.T. (2010) Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncology, 11(9), p. 819. (doi: 10.1016/S1470-2045(10)70163-7)
Meredith, P.A., Murray, L. and McInnes, G.T. (2010) Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension. Journal of Human Hypertension, 24(8), pp. 525-531. (doi: 10.1038/jhh.2009.99)
Dolan, E., Stanton, A., Thom, S., Caulfield, M., Atkins, N., McInnes, G., Collier, D., Dicker, P. and O'Brien, E. (2009) Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients - an Anglo-Scandinavian cardiac outcomes trial substudy. Journal of Hypertension, 27(4), pp. 876-885.
McInnes, G. T. (2009) Drug treatment of prehypertension: Not now, not ever? Blood Pressure, 18(6), pp. 304-307. (doi: 10.3109/08037050903416436)
McInnes, G.T. (2009) Telmisartan to prevent recurrent stroke - the PRoFESS study: was the baby thrown out with the bathwater? Stroke, 40(5), pp. 1938-1940. (doi: 10.1161/STROKEAHA.108.541276)
McMahon, A. D. , Conway, D. I. , MacDonald, T. M. and McInnes, G. T. (2009) The unintended consequences of clinical trials regulations. PLoS Medicine, 6(11), e1000131. (doi: 10.1371/journal.pmed.1000131)
Stewart, L., McInnes, G.T., Murray, L., Sloan, B., Walters, M., Morton, R., Padmanabhan, S., Reid, J.L. and Morrison, D.S. (2009) Risks of socioeconomic deprivation on mortality in hypertensive patients. Journal of Hypertension, 27(4), pp. 730-735. (doi: 10.1097/HJH.0b013e328324ed58)
McManus, F., McInnes, G. T. and McConnell, J. M. C. (2008) Drug Insight: eplerenone, a mineralocorticoid-receptor antagonist. Nature Reviews Endocrinology, 4(1), pp. 44-52. (doi: 10.1038/ncpendmet0676)
Kjeldsen, S. et al. (2008) Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: The VALUE trial. Blood Pressure, 17(3), pp. 170-177. (doi: 10.1080/08037050802169644)
Schmieder, R., Kjeldsen, S., Julius, S., McInnes, G., Zanchetti, A. and Hua, T. (2008) Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. Journal of Hypertension, 26(3), pp. 403-411.
Hua, T., Jamerson, K., Julius, S., McInnes, G., Ruilope, L., Segura, J., Stolt, P., Weber, M. and Zanchetti, A. (2007) Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. Journal of Hypertension, 25, pp. 1473-1479.
McInnes, G. (2007) Antihypertensive drugs in combination: additive or greater than additive? Journal of Human Hypertension, 21(12), pp. 914-916.
McInnes, G. (2007) Renin inhibition: the holy grail of renin-angiotensin system blockade? Journal of Human Hypertension, 21(10), pp. 766-769.
McInnes, G. (2007) What is the true place of blood pressure in cardiovascular risk management? Journal of Hypertension, 25, pp. 925-928.
Parthasarathy, H.K., Alhashmi, K., McMahon, A., Struthers, A.D., Connell, J.M.C., McInnes, G.T., Ford, I. and MacDonald, T.M. (2007) Does the aldosterone : renin ratio predict the efficacy of spironolactone over bendroflumethiazide in hypertension? A clinical trial protocol for RENALDO (RENin-ALDOsterone) study. BMC Cardiovascular Disorders, 7(14), (doi: 10.1186/1471-2261-7-14)
Amerena, J. et al. (2006) The valsartan antihypertensive long-term use evaluation (VALUE) trial - Outcomes in patients receiving monotherapy. Hypertension, 48, pp. 385-391. (doi: 10.1161/01.HYP.0000236119.96301.f2)
Coca, A. et al. (2006) Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. Journal of Hypertension, 24(7), pp. 1405-1412.
MacDonald, T., McInnes, G., Mitchell, M., Patterson, D. and Webster, J. (2006) Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension. British Journal of Clinical Pharmacology, 62(3), pp. 280-287.
McInnes, G., Burke, T. and Carides, G. (2006) Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Journal of Human Hypertension, 20, pp. 51-58. (doi: 10.1038/sj.jhh.1001939)
Sever, P. et al. (2006) Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. European Heart Journal, 27, pp. 2982-2988. (doi: 10.1093/eurheartj/ehl403)
Zanchetti, A., Julius, S., Kjeldsen, S., McInnes, G., Hua, T., Weber, M., Laragh, J. and Plat, F. (2006) Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from value. Journal of Hypertension, 24, S4-S4.
Aslanyan, S., Weir, C., McInnes, G., Reid, J., Walters, M. and Lees, K. (2005) Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. European Journal of Neurology, 12, pp. 493-498.
Beevers, D. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A. Lancet, 366(9489), pp. 895-906.
Beevers, D. et al. (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 366, pp. 907-913. (doi: 10.1016/S0140-6736(05)67186-3)
Beevers, G. et al. (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care, 28, pp. 1151-1157.
Dahlof, B. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-B. Lancet, 366, pp. 895-906. (doi: 10.1016/S0140-6736(05)67185-1)
McInnes, G. (2005) Antioxidants and hypertension: another false dawn? Journal of Hypertension, 23(11), pp. 1963-1966.
McInnes, G. (2005) Lowering blood pressure for cardiovascular risk reduction. Journal of Hypertension, 23, S3-S8.
McInnes, G., Ruilope, L., Volpe, M., Waeber, B. and Weber, M. (2005) Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? Journal of Human Hypertension, 19, pp. 331-339. (doi: 10.1038/sj.jhh.1001831)
Stergiou, G., Efstathiou, S., Inglis, G., Connell, J., McInnes, G. and Mountokalakis, T. (2005) Association of renin-angiotensin system gene polymorphisms with antihypertensive responses to angiotensin-converting enzyme inhibition or angiotensin receptor blockade. Journal of Human Hypertension, 19, pp. 971-974. (doi: 10.1038/sj.jhh.1001918)
Weber, M.A. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet, 363(9426), pp. 2049-2051. (doi: 10.1016/S0140-6736(04)16456-8)
McInnes, G.T. (2004) How important is optimal blood pressure control? Clinical Therapeutics, 26(Suppl.), A3-A11. (doi: 10.1016/S0149-2918(04)90140-3)
Beevers, G. et al. (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre r. Drugs, 64, pp. 43-60.
Bohm, M., McInnes, G., Neutel, J. and Unger, T. (2004) The role of olmesartan medoxomil in the management of hypertension. Drugs, 64, pp. 2731-2739.
Brown, M., Davis, M., McInnes, G., Potter, J., Poulter, N., Sever, P., Thom, S. and Williams, B. (2004) Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004 - BHSIV. Journal of Human Hypertension, 18, pp. 139-185. (doi: 10.1038/sj.jhh.1001683)
Brown, M., Davis, M., McInnes, G., Potter, M., Poulter, N., Sever, P., Thom, S. and Williams, B. (2004) British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. British Medical Journal, 328, pp. 634-640.
Kjeldsen, S. and McInnes, G. (2004) Never mind the quality, feel the width - ALLHAT revisited. Blood Pressure, 13, pp. 330-334. (doi: 10.1080/08037050410004576)
McInnes, G. (2004) Hypertension control - An old song resung. Blood Pressure, 13(2), pp. 69-71.
McInnes, G. (2004) What lies behind the intense criticism of ALLHAT? Reply. Journal of Hypertension, 22(1), pp. 226-227.
Sever, P. et al. (2004) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid lowering arm (ASCOT-LLA): A multicentre randomi. Drugs, 64, pp. 43-60.
Aslanyan, S., Lees, K., McInnes, G., Reid, J. and Weir, C. (2003) Effect of area-based deprivation on the severity, subtype, and outcome of ischemic stroke. Stroke, 34, pp. 2623-2628. (doi: 10.1161/01.STR.0000097610.12803.D7)
Beevers, G. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre ran. Lancet, 361(9364), pp. 1149-1158.
Julius, S. et al. (2003) VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. American Journal of Hypertension, 16, pp. 544-548. (doi: 10.1016/S0895-7061(03)00904-X)
MacDonald, T., McInnes, G. and Wong, S. (2003) Why not prescribe the best drugs for hypertension now? Journal of Human Hypertension, 17(7), pp. 505-511.
Mancia, G. et al. (2003) 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension, 21, pp. 1011-1053. (doi: 10.1097/01.hjh.0000059051.65882.32)
McInnes, G. (2003) ALLHAT: a saga of missed opportunities. Journal of Human Hypertension, 17(6), pp. 373-377.
McInnes, G. (2003) The expanding role of angiotension receptor blockers in the management of the elderly hypertensive. Current Medical Research and Opinion, 19, pp. 452-455. (doi: 10.1185/030079903125001992)
McInnes, G. (2003) Introduction: the role of angiotensin receptor blockers in preventing stroke and cognitive decline. Current Medical Research and Opinion, 19(5), p. 437.
McInnes, G. (2003) Size isn't everything - ALLHAT in perspective. Journal of Hypertension, 21(3), pp. 459-461.
Patterson, D., Webster, J., McInnes, G., Brady, A. and MacDonald, T. (2003) The effects of KT3-671, a new angiotensin II (AT 1) receptor blocker in mild to moderate hypertension. British Journal of Clinical Pharmacology, 56, pp. 513-519. (doi: 10.1046/j.1365-2125.2003.01932.x)
Sever, P. et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomise. Lancet, 361, pp. 1149-1158.
Elliott, H.I. and McInnes, G.T. (2002) Special management needs of the elderly hypertensive patient. Journal of the Renin-Angiotensin-Aldosterone System, 3, S25-S31.
McInnes, G. (2002) Clinical trials and tribulations. Clinical and Experimental Pharmacology and Physiology, 29, pp. 951-955.
McInnes, G. (2002) Olmesartan medoxomil. Drugs, 62(9), p. 1356.
McInnes, G. (2002) Systolic hypertension as a cardiovascular risk factor. Blood Pressure, 11, pp. 134-143.
Atkins, N., Caulfield, M., McInnes, G., Nichol, F., O'Brien, E., Stanton, A. and Thom, S. (2001) Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients. Journal of Human Hypertension, 15, S47-S51.
Beevers, G. et al. (2001) Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol. Journal of Human Hypertension, 15, S11-S12.
Beevers, G. et al. (2001) Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian cardiac outcomes trial. Journal of Hypertension, 19, pp. 1139-1147.
Dahlof, B. et al. (2001) Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. Journal of Hypertension, 19, pp. 1149-1159.
Kjeldsen, S. et al. (2001) Characteristics of 15314 hypertensive patients at high coronary risk. The VALUE Trial. Blood Pressure, 10, pp. 83-91.
McInnes, G. (2001) Angiotensin II antagonists in systolic blood pressure control. Hospital Medicine, 62, pp. 773-777.
McInnes, G. (2001) Clinical potential: angiotensin converting enzyme inhibitor or angiotensin II antagonists? Journal of Hypertension, 19(Suppl.), S61-S67.
McInnes, G. (2001) Debate: Does it matter how you lower blood pressure? Current Controlled Trials in Cardiovascular Medicine, 2(2), pp. 63-66.
McInnes, G. (2001) Lessons from the recent trials on hypertension treatment. Nephrology Dialysis Transplantation, 16, pp. 43-45.
McMurray, J. and McInnes, G. T. (1992) The J-curve hypothesis. Lancet, 339(8792), pp. 561-562. (doi: 10.1016/0140-6736(92)90390-o) (PMID:1346917)
Books
Elliot, H.J., Connell, J.M.C. and McInnes, G.T. (2003) Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK. ISBN 9780953733941
Book Sections
McInnes, G.T. (2007) Diabetes and hypertension. In: Fisher, M. and McMurray, J.J. (eds.) Diabetic Cardiology. Series: Diabetes in practice. Wiley: Chichester, pp. 135-174. ISBN 9780470862049
Rennie, I.G. and McInnes, G.T. (2007) Medication. In: Cox, R.A.F., Brown, I. and Palmer, K.T. (eds.) Fitness for Work: the Medical Aspects. Oxford University Press: Oxford, pp. 547-562. ISBN 9780199215652
Julius, S. et al. (2005) The VALUE trial. In: Oparil, S. and Weber, M.A. (eds.) Hypertension: A Companion to Brenner and Rector's The Kidney. Elsevier Mosby: Philadelphia, USA, pp. 366-375. ISBN 9780721602585
McInnes, G.T. (2005) Critical assessment of hypertension guidelines. In: Weber, M.A. (ed.) Hypertension: A Companion Guide to Brenner and Rector's the Kidney. Elsevier: Philadelphia, pp. 391-399. ISBN 9780721602585
McInnes, G.T., Curzio, J.L. and Kennedy, S. (2004) Hypertension and antihypertensive therapy. In: Lindsay, G.M. and Gaw, A. (eds.) Coronary Heart Disease Prevention: A Handbook for the Health-Care Team. Churchill Livingstone: Edinburgh, UK. ISBN 9780443071171
Elliot, H.L. and McInnes, G.T. (2003) Calcium channel blockers in profile. In: Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services Limited: Oxford, pp. 323-336. ISBN 9780953733941
McInnes, G.T. (2003) Ongoing trials. In: Elliott, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 89-126. ISBN 9780953733941
McInnes, G.T. (2003) Recent trial results. In: Elliot, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 2-34. ISBN 9780953733941
McInnes, G. (2002) Evidence-based management of hypertension. In: Horizons in Medicine Vol. 13. Royal College of Physicians: London. ISBN 1-86016-154-5
McInnes, G.T. (2001) Current guidelines. In: Elliott, H.L., Connell, J.M.C. and McInnes, G.T. (eds.) The Year in Hypertension 2001. Clinical Publishing Services: Oxford, UK, pp. 43-88. ISBN 9780953733941
McInnes, G.T. (2001) Diuretics. In: Aronson, J.K. (ed.) Side Effects of Drugs Annual 24: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions. Elsevier: Amsterdam, The Netherlands, pp. 246-252. ISBN 9780444505125